Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

New Figures Highlight Hidden Human Cost Of Alcohol Misuse In Scotland
Commenting on new figures published yesterday which show that one in 20 deaths are attributable to alcohol, Dr Peter Terry, Chairman of the BMA in Scotland, said:
new payday loan lenders
Real Time Snapshot Of The Learning Process
To learn from experience, it is essential to know whether a past action was associated with a desired outcome. Now, scientists have demonstrated how this information can be coded by a single cell. The research, published in the July 30th issue of the journal Neuron, provides strong support for a neural mechanism that allows reward signals to be combined over time to drive successful learning.
News of the day
Obama Names NYC Health Commissioner Frieden Next CDC Director
President Obama on Friday named New York City Health Commissioner Thomas Frieden as the new director of the Centers for Disease Control and Prevention, the New York Times reports. It has long been expected that Obama would select Frieden, an infectious disease specialist who is "widely admired" in the public health arena, according to the Times. In his seven years as health commissioner of New York City, Frieden pushed to establish HIV testing as a part of routine medical exams and defended a condom-distribution program that hands out more than 35 million condoms annually. Frieden is expected to take office in June and does not require Senate confirmation for the position. He will replace Richard Besser, the current acting director of CDC, who will return to his position as head of CDC"s coordinating office for terrorism preparedness and emergency response.The Times reports that Frieden will "inherit a host of immediate and long-term problems" at CDC, including organizational issues, low morale and the Obama administration"s health care reform agenda. "Health care reform also needs to be on his plate," Jeffrey Koplan, who served as CDC director from 1998 to 2002, said, adding, "There is a huge opportunity there to improve public health, and it"s one in which any CDC director will want to be a player." Several health care advocates praised the appointment, according to the Times. Dennis deLeon, president of the Latino Commission on AIDS in New York City said that Frieden is "willing to challenge the status quo in an effort to make a difference." Jeffrey Levi, executive director of the not-for-profit Trust for America"s Health, said Frieden is a "transformational leader" who "can take public health to a new place" (Harris/Hartocollis, New York Times, 5/15).
Public Health

Competitive Technologies' Pain Therapy Medical Device To Be Used In Independent Clinical Study

Competitive Technologies, Inc. (NYSE Amex: CTT) announced today that CTT"s pain therapy medical device will be used by clinical investigators at the Virginia Commonwealth University Massey Cancer Center for a Phase II independent clinical study. The study will examine the ability of CTT"s U.S. FDA-cleared device to decrease pain associated with chemotherapy-induced peripheral neuropathy (CIPN). "We are very proud to be able to offer this breakthrough device for clinical research study at VCU Massey Cancer Center, a National Cancer Institute-designated center that helps lead our nation"s cancer research agenda," said John B. Nano, CTT"s Chairman, President and CEO. "The device treats pain without the harmful side effect of most drugs, including morphine. This technology brings CTT to the forefront in providing a solution to the needs of cancer patients and the improvement of palliative healthcare in the U.S. and globally. This medical device is a prime example of our strategy to connect clinical science to patient care." Massey is the first site in the U.S. to offer a clinical study for pain in cancer patients with this device. Two international leaders in palliative care and pain management at Massey, Patrick Coyne, RN MSN, and Tom Smith, MD, the Massey Endowed Chair in Palliative Care Research, sought out CTT"s device after learning of its positive results from a pilot study for patients with pain. "CIPN can be a very debilitating side effect for some 20-30 percent of cancer patients, affecting their hands and feet with sharp pain," Dr. Smith said. "If we can minimize the opioids given to patients and reduce or eliminate pain through non-invasive procedures, we will improve quality of life for cancer patients, and create a major shift in how pain is treated in America." Massey has received IRB approval for its study and expects to begin enrolling patients on the trial this summer. The treatment protocol calls for 15 patients with chemotherapy-induced neuropathy to be studied first. About the Device The medical device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The device has U.S. FDA clearance for sales in the U.S., as well as Medical Device CE certification from the E.U. allowing sales throughout Europe and several other countries. CTT has exclusive worldwide rights to this device. The unit, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. CTT"s partner, GEOMC Co. Ltd. of Korea is manufacturing the device commercially for worldwide distribution. CTT has developed a financing unit, Competitive Technologies Financial Services (CFS), which offers customers opportunities for leasing of CTT"s pain therapy medical device in the U.S. market. For more information on the device, visit http://www.CalmareTT.com. The device has been used on over 3,000 patients in Europe, including at the Pain Management Center at Tor-Vergata University Medical Center in Rome (http://www.ptvonline.it/uo_ter_ant_ing.asp). Developed in Italy by CTT"s client, Prof. Giuseppe Marineo, the technology was brought to CTT through the efforts of the Zangani Investor Community™. Aris D. Despo, CTT"s Executive VP, Business Development, noted, "We are pleased to know that national leaders at Massey will be conducting the CIPN independent study with our therapy unit. Their expertise in clinical research and in relieving pain and suffering for people with cancer ensures that the study will yield scientifically valid information as we endeavor to make this therapy more readily available in the U.S." Massey has the largest menu of clinical trials in Virginia, offering patients some of the latest treatments and technologies available. In addition, Massey is one of only six national centers designated by the Robert Woods Johnson Foundation as a Palliative Care Leadership Center, through which Dr. Smith and colleagues train other professionals from across the country in how to develop and administer palliative care programs, which include pain and symptom management. Competitive Technologies, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009